Showing results (21-30 of 68) with videos related to
Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2008
Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancerChandra P Belani, Suresh Ramalingam, Michael C Perry, et al.Clinical Lung Cancer|September 7, 2021
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung CancerDirk De Ruysscher, Suresh Ramalingam, James Urbanic, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2008
Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I studySuresh Ramalingam, Judy Forster, Cynthia Naret, et al.Lung Cancer (Amsterdam, Netherlands)|December 3, 2014
Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort studyCorey Langer, Arliene Ravelo, Sebastien J Hazard, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 14, 2017
Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and ComplexitySandra Garcia, Ajit Bisen, Jingsheng Yan, et al.Clinical Lung Cancer|March 4, 2016
Evaluating Intensity-Modulated Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer: Results From the National Cancer Data BaseNaresh Jegadeesh, Yuan Liu, Theresa Gillespie, et al.Cancer|May 31, 2008
Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancerSuresh Ramalingam, Michael C Perry, Renato V La Rocca, et al.Clinical Lung Cancer|July 21, 2022
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 BlockadeBadi El Osta, Jennifer Carlisle, Conor Steuer, et al.Journal of the American College of Surgeons|July 25, 2015
Nonclinical Factors Associated with 30-Day Mortality after Lung Cancer Resection: An Analysis of 215,000 Patients Using the National Cancer Data BaseJohn N Melvan, Manu S Sancheti, Theresa Gillespie, et al.Drug Development Research|January 5, 2019
Graph theoretical analysis, in silico modeling, prediction of toxicity, metabolism and synthesis of novel 2-(methyl/phenyl)-3-(4-(5-substituted-1,3,4-oxadiazol-2-yl) phenyl) quinazolin-4(3H)-ones as NMDA receptor inhibitorGovindaraj Saravanan, Theivendren Panneerselvam, Selvaraj Kunjiappan, et al.Pageof 7